Nicholson Garry A 4

What Happened
Garry A. Nicholson, a director of TScan Therapeutics, was granted a derivative award covering 67,000 shares on May 20, 2026. The Form 4 reports the acquisition as an award (transaction code A) with an acquisition price of $0.00 (i.e., no cash paid for the award at grant). This is a compensatory option/award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-20; Form 4 filed 2026-05-22 (appears timely, within the typical two-business-day window).
• Award: 67,000 shares (derivative); reported acquisition price $0.00; total reported value $0.
• Vesting/Exercise: Footnote — "The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."
• Shares owned after transaction: not specified in the provided summary of the filing.
• Transaction type: Grant/award of a derivative (option); not an exercise or sale.

Context
This appears to be a typical director compensation grant that vests contingent on continued service (either by May 20, 2027 or the next annual meeting). Such awards do not represent an immediate purchase of stock or a realization of cash and should be viewed as part of routine compensation rather than a direct market sentiment signal.